Immunological aspect of the liver and metastatic uveal melanoma

Abstract

Uveal (eye) melanoma is the most common primary eye malignancy in adults. Despite optimal treatments for primary uveal melanoma, up to 50% of patients subsequently develop systemic metastasis, often in the liver. Once hepatic metastasis develops, the survival of patients is generally short and currently available treatments fail to show meaningful improvement of survival. Recent development of immune checkpoint blockades revolutionized immunotherapy for metastatic cutaneous (skin) melanoma. Unfortunately, metastatic uveal melanoma is unresponsive to this approach, thus there is an unmet need to improve the treatment of metastatic uveal melanoma. One unique characteristic of uveal melanoma is that the majority of metastases first develop in the liver. The liver is highly specialized in development of immune tolerance to food-derived antigens and consequently serves a unique function in the immune system. Understanding the mechanisms by which the liver orchestrates immune-related responses is important to the development of an effective immunotherapy for hepatic metastases such as metastatic uveal melanoma. In this review article, the authors overview the immunological aspects of the liver and discuss approaches to improve immunotherapy for metastatic uveal melanoma.

Keywords

Uveal melanoma / metastasis / liver / liver microenvironment / immunotherapy

References

[1] Kaliki S,Shields JA.Uveal melanoma: estimating prognosis..Indian J Ophthalmol2015;63:93-102 PMCID:PMC4399142

[2] Collaborative Ocular Melanoma Study Group..Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15..Arch Ophthalmol2001;119:670-6

[3] Ewens KG,Richards-Yutz J,Shields CL,Ganguly A.Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma..Invest Ophthalmol Vis Sci2014;55:5160-7

[4] Damato B,Taktak AF.Estimating prognosis for survival after treatment of choroidal melanoma..Prog Retin Eye Res2011;30:285-95

[5] Singh AD,Topham AK.Uveal melanoma: trends in incidence, treatment, and survival..Ophthalmology2011;118:1881-5

[6] Malina HZ.Indoleamine 2,3-dioxygenase: antioxidant enzyme in the human eye..Graefes Arch Clin Exp Ophthalmol1996;234:457-62

[7] Bronkhorst IH,Jordanova ES,Burg SH.Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma..Invest Ophthalmol Vis Sci2012;53:5370-8

[8] Bronkhorst IH,Jordanova ES,Versluis M,Jager MJ.Detection of M2-macrophages in uveal melanoma and relation with survival..Invest Ophthalmol Vis Sci2011;52:643-50

[9] Makitie T,Tarkkanen A.Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma..Invest Ophthalmol Vis Sci2001;42:1414-21

[10] Mougiakakos D,Trocme E,Economou MA,Seregard S.Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma..Cancer2010;116:2224-33

[11] Vetter CS,Brocker EB.Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma..Br J Cancer2004;91:1495-9

[12] Elinav E,Thaiss CA,Jin C.Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms..Nat Rev Cancer2013;13:759-71

[13] Vidal-Vanaclocha F.The prometastatic microenvironment of the liver..Cancer Microenviron2008;1:113-29 PMCID:PMC2654354

[14] Bakalian S,Logan P,Maloney S,Martins C,Burnier MN, Jr..Molecular pathways mediating liver metastasis in patients with uveal melanoma..Clin Cancer Res2008;14:951-6

[15] van den Bosch T,Vaarwater J,de Klein A.Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance..Invest Ophthalmol Vis Sci2013;54:7354-61

[16] Li H,Niederkorn JY.Differential expression of chemokine receptors on uveal melanoma cells and their metastases..Invest Ophthalmol Vis Sci2008;49:636-43

[17] Yoshida M,McCue PA,Baserga R,Rui H,Sato T.Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth..Pigment Cell Melanoma Res2014;27:297-308

[18] Economou MA,Bykov V,Bartolazzi A,Seregard S.Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications..Invest Ophthalmol Vis Sci2005;46:4372-5

[19] Helgadottir H.The genetics of uveal melanoma: current insights..Appl Clin Genet2016;9:147-55 PMCID:PMC5019476

[20] van den Bosch T,Paridaens D.Genetics of uveal melanoma and cutaneous melanoma: two of a kind?.Dermatol Res Pract2010;2010:360136

[21] Harbour JW,Roberson ED,Cao L,Council ML,Helms C.Frequent mutation of BAP1 in metastasizing uveal melanomas..Science2010;330:1410-3 PMCID:PMC3087380

[22] Kalirai H,Faqir S,Coupland SE.Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing..Br J Cancer2014;111:1373-80 PMCID:PMC4183849

[23] McCarthy C,Lake SL,Damato BE.Insights into genetic alterations of liver metastases from uveal melanoma..Pigment Cell Melanoma Res2016;29:60-7

[24] Trolet J,Huon I,Decraene C,Sastre-Garau X,Thiéry JP,Asselain B,Mariani P,Barillot E.Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases..Invest Ophthalmol Vis Sci2009;50:2572-80

[25] Van den Eynden GG,Illemann M,Bird NC,Eefsen RL,Brodt P.The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications..Cancer Res2013;73:2031-43

[26] Bai L,Cao CP.Effects of inflammatory cytokines on the recurrence of liver cancer after an apparently curative operation..J Dig Dis2007;8:154-9

[27] Martin-Padura I,Lauri D,Sanchez-Madrid F,Mantovani A,Dejana E.Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression..Cancer Res1991;51:2239-41

[28] Zhu B,Zhang M,Cheng H,Ling Y,Xu R.Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma..J Transl Med2015;13:365 PMCID:PMC4655083

[29] Racanelli V.The liver as an immunological organ..Hepatology2006;43:S54-62

[30] Jenne CN.Immune surveillance by the liver..Nat Immunol2013;14:996-1006

[31] Naito M,Takahashi K.Development, differentiation, and maturation of Kupffer cells..Microsc Res Tech1997;39:350-64

[32] Bilzer M,Gerbes AL.Role of Kupffer cells in host defense and liver disease..Liver Int2006;26:1175-86

[33] Kimura Y,Hangai S,Negishi H,Yamasaki S,Yanai H.The innate immune receptor Dectin-2 mediates the phagocytosis of cancer cells by Kupffer cells for the suppression of liver metastasis..Proc Natl Acad Sci U S A2016;113:14097-102 PMCID:PMC5150405

[34] Yin C,Asahina K.Hepatic stellate cells in liver development, regeneration, and cancer..J Clin Invest2013;123:1902-10 PMCID:PMC3635734

[35] Cheng H,Kageyama K,McCue PA,Aplin AE.Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma..Cancer Res2015;75:2737-48 PMCID:PMC4490069

[36] Martin D,Gutkind JS.CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex..J Biol Chem2009;284:6038-42 PMCID:PMC2649103

[37] Norris CA,Kang LI,Radder JE,Yang Y,Bowen WC,Michalopoulos GK,Mars WM.Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli..PLoS One2014;9:e96053 PMCID:PMC3999098

[38] Grossniklaus HE,You S,Heegaard S.Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns..Hum Pathol2016;57:165-75

[39] Male V.Liver-resident NK cells: the human factor..Trends Immunol2017;38:307-9

[40] Bandyopadhyay K,Kumar V.NKT cell subsets as key participants in liver physiology and pathology..Cell Mol Immunol2016;13:337-46 PMCID:PMC4856801

[41] Tiegs G.Immune tolerance: what is unique about the liver..J Autoimmun2010;34:1-6

[42] Franceschini D,Francavilla V,Morrone S,Cerino A,Barnaba V.PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV..J Clin Invest2009;119:551-64 PMCID:PMC2648671

[43] Pilotte L,Stroobant V,Dolusic E,De Plaen E,Wouters J,Van den Eynde BJ.Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase..Proc Natl Acad Sci U S A2012;109:2497-502 PMCID:PMC3289319

[44] Platten M,Oezen I,Ochs K.Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors..Front Immunol2014;5:673

[45] Crispe IN.Hepatic T cells and liver tolerance..Nat Rev Immunol2003;3:51-62

[46] Schildberg FA,Turley SJ.Hepatic immune regulation by stromal cells..Curr Opin Immunol2015;32:1-6

[47] Ozaki S,Kageyama K,Ohara M,Manser T,Aplin AE.Establishment and characterization of orthotopic mouse models for human uveal melanoma hepatic colonization..Am J Pathol2016;186:43-56 PMCID:PMC4715216

[48] Robinson MW,O'Farrelly C.Liver immunology and its role in inflammation and homeostasis..Cell Mol Immunol2016;13:267-76 PMCID:PMC4856809

[49] Krishna Y,Kalirai H.Inflammatory cell infiltrates in advanced metastatic uveal melanoma..Hum Pathol2017;66:159-66

[50] Vidal-Vanaclocha F,Mendoza L,Anasagasti MJ,Carrascal T,Reznikov LL,Novick D,Dinarello CA.IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1..Proc Natl Acad Sci U S A2000;97:734-9 PMCID:PMC15399

[51] Tecchio C,Cassatella MA.Neutrophil-derived cytokines: facts beyond expression..Front Immunol2014;5:508 PMCID:PMC4204637

[52] Auguste P,Wang N,Bikfalvi A.The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation..Am J Pathol2007;170:1781-92 PMCID:PMC1854970

[53] Kumar V,Tcyganov E.The nature of myeloid-derived suppressor cells in the tumor microenvironment..Trends Immunol2016;37:208-20 PMCID:PMC4775398

[54] Qin Y,Reuben A,Haymaker C,Spencer CN,Reddy S,Fulbright OJ,Wahl A,Thorsen ST,Conrad C,Tetzlaff MT,Gombos DS,Amaria RN,Wargo JA,Patel SP.Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: a pilot study..Oncoimmunology2017;6:e1321187 PMCID:PMC5486182

[55] Yamamoto A,Sullivan KL,Gonsalves CF,Berd D,Shields CL,Sato T.High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma..Radiology2009;252:290-8

[56] Valsecchi ME,Eschelman DJ,Chervoneva I,Shields CL,Sullivan KL,Berd D,Sato T.Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases..J Vasc Interv Radiol2015;26:523-32.e2 PMCID:PMC4417549

[57] Hodi FS,McDermott DF,Sosman JA,Gonzalez R,Schadendorf D,Akerley W,Lutzky J,Vaubel JM,Hogg D,Lebbé C,Quirt I,Wolchok JD,Tian J,Nichol GM,Urba WJ.Improved survival with ipilimumab in patients with metastatic melanoma..N Engl J Med2010;363:711-23 PMCID:PMC3549297

[58] Robert C,Bondarenko I,Weber J,Lebbe C,Testori A,Davidson N,Maio M,Miller WHJr,Lotem M,Ibrahim R,Chen TT,Hoos A.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma..N Engl J Med2011;364:2517-26

[59] Topalian SL,McDermott DF,Carvajal RD,Brahmer JR,Atkins MB,Leming PD,Puzanov I,Taube JM,Kollia GD,Pardoll DM,Hodi FS.Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab..J Clin Oncol2014;32:1020-30 PMCID:PMC4811023

[60] Algazi AP,Shoushtari AN,Eroglu Z,Ott PA,Hwang J,Sosman JA,Chmielowski B,Weber JS.Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies..Cancer2016;122:3344-53

[61] Maio M,Chiarion-Sileni V,Parmiani G,De Rosa F,Di Guardo L,Picasso V,De Galitiis F,Guida M,Ascierto PA.Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma..Ann Oncol2013;24:2911-5

[62] Luke JJ,Postow MA,Ramaiya N,Giobbie-Hurder A,Ibrahim N,Flaherty KT,Harding JJ,Dickson M,Chapman PB,Hodi FS.Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience..Cancer2013;119:3687-95 PMCID:PMC3986037

[63] Javed A,Johnston C,Orloff MM,Sato T.Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma..J Clin Oncol2016;ASCO 2016:abstract 9541

[64] Tumeh PC,Hamid O,Loo KL,Rosenblum M,Taube JM,Khurana N,Krummel MF,Sosa EV,Banayan N,Nguyen-Kim DL,Shintaku IP,Taylor EJ,Algazi AP,Dummer R,Elashoff D,Goldinger SM,Pierce RH.Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC..Cancer Immunol Res2017;5:417-24

[65] Chandran SS,Yang JC,Klebanoff CA,Wunderlich JR,Zlott D,Sabesan AC,Xi L,Raffeld M,Toomey MA,Kammula US.Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study..Lancet Oncol2017;18:792-802

[66] Rothermel LD,Stephens DJ,Paria BC,Somerville R,Lee CC,Pham TH,Jailwala P,Kammula US.Identification of an immunogenic subset of metastatic uveal melanoma..Clin Cancer Res2016;22:2237-49 PMCID:PMC4854785

[67] de Vries TJ,Ruiter DJ.High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma..Br J Cancer1998;78:1156-61 PMCID:PMC2063001

[68] Bol KF,Aarntzen EH,Keunen JE,de Klein A,Paridaens D,de Vries IJ.Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients..Am J Ophthalmol2014;158:939-47

[69] Middleton MR,Sznol M,Mulatero C,Steven N,Shingler WH,Hassan NJ.A phase I/IIa study of IMCgp100: partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma..Cancer Res2015;75:abstract CT106

[70] Sato T,Hernandez-Aya LF,Orloff MM,McAlpine C,Lanasa MC,Carvajal RD.Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma..J Clin Oncol2017;ASCO 2017:abstract 9531

[71] Esmaeli B,Soheili A,Simantov R.GPNMB expression in uveal melanomas: a potential for targeted therapy..Invest Ophthalmol Vis Sci2009;50:3385

[72] Patel S, Lewis KD, Olencki T, Hernandez-Aya L, Joseph R, Williamson S, Chandra S, Shirai K, Moscow J. A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. Avaliable from: http://www.melanomacongress.com/docs/2017_abstracts.pdf. [Last accessed on 23 Oct 2017]